Dashboard
Manage Tickers

TVRD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Raymond James Downgrades Tvardi Therapeuti...
10/14/2025 14:11:28

Raymond James analyst Ryan Deschner downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Outperform to Market Perform.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 12:09:03

tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks
Tvardi Therapeutics' Lung Disease Candidat...
10/13/2025 18:23:45

Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and...

gold-rises-over-3-tvardi-therapeutics-shares-plunge
Gold Rises Over 3%; Tvardi Therapeutics Sh...
10/13/2025 17:12:39

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
10/13/2025 17:06:02

Core News & Articles
BTIG Maintains Buy on Tvardi Therapeutics,...
10/13/2025 15:37:26

BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $55 to ...

dow-surges-1-fastenal-shares-fall-after-q3-results
Dow Surges 1%; Fastenal Shares Fall After ...
10/13/2025 13:55:08

Core News & Articles
Barclays Initiates Coverage On Tvardi Ther...
10/13/2025 12:14:49

Barclays analyst Etzer Darout initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
10/13/2025 12:08:59

Core News & Articles
Tvardi Therapeutics Said Preliminary Data ...
10/13/2025 11:32:36

The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in ...

Core News & Articles
Tvardi Therapeutics Says On Track For Mult...
08/14/2025 21:07:01

Core News & Articles
Tvardi Therapeutics Q2 EPS $(1.00) Misses ...
08/14/2025 20:33:23

Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of...

Core News & Articles
Raymond James Initiates Coverage On Tvardi...
07/14/2025 14:50:50

Raymond James analyst Ryan Deschner initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and ann...

Core News & Articles
Cantor Fitzgerald Initiates Coverage On Tv...
07/11/2025 12:00:31

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating a...

recently-listed-tvardi-therapeutics-lead-drug-positioned-to-drive-broad-improvement-analyst-sees-over-150-stock-upside
Recently Listed Tvardi Therapeutics' Lead ...
06/12/2025 19:07:56

Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway int...

this-modine-manufacturing-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Modine Manufacturing Analyst Begins C...
06/12/2025 12:38:11

Core News & Articles
Piper Sandler Initiates Coverage On Tvardi...
06/12/2025 09:27:44

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and an...

Core News & Articles
Tvardi Therapeutics Files Prospectus Relat...
05/30/2025 20:18:24

-SEC Filing

Core News & Articles
Tvardi Therapeutics Completes Enrollment F...
05/27/2025 12:06:32

Topline data from the REVERT IPF trial anticipated in 4Q 2025Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clin...

Core News & Articles
Oppenheimer Initiates Coverage On Tvardi T...
05/21/2025 15:13:36

Oppenheimer analyst Jay Olson initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and announces...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION